[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591396":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":10,"centralContacts":31,"locations":37,"responsibleParty":62,"collaborators":10,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":10,"overallStatus":80,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Xijing Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Group one",null,"Intestinal cancer patients undergoing primary surgical treatment",[13],"Other: Multi-gene methylation testing",{"label":15,"type":10,"description":16,"interventionNames":17},"Group two","Intestinal cancer patients undergoing surgery following neoadjuvant therapy",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group three","Intestinal cancer patients undergoing active surveillance following neoadjuvant therapy",[13],[23,27,29],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Multi-gene methylation testing","Undergo multi-gene methylation testing in blood during follow-up",[9],{"type":6,"name":24,"description":25,"armGroupLabels":28,"otherNames":10},[19],{"type":6,"name":24,"description":25,"armGroupLabels":30,"otherNames":10},[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Zhongyang Zhang","CONTACT","+86 18831363219","18831363219@163.com",[38,55],{"facility":39,"status":10,"city":40,"state":41,"zip":10,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Tangdu Hospital","Xi'an","Shaanxi","China","CN",{"type":45,"coordinates":46},"Point",[47,48],108.92861,34.25833,{"lat":48,"lon":47},[51],{"name":52,"role":34,"phone":53,"phoneExt":10,"email":54},"Xianchun Gao, doctor","+86 18165302960","gigaoxc@163.com",{"facility":5,"status":10,"city":40,"state":41,"zip":10,"country":42,"countryCode":43,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},{"type":45,"coordinates":57},[47,48],{"lat":48,"lon":47},[60],{"name":33,"role":34,"phone":61,"phoneExt":10,"email":36},"+86 188 3136 3219",{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100591396","investigating-multigene-methylation-dynamics-in-treatment-response-surveillance-for-intestinal-carcinoma-100591396",false,"NCT06979882","Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Intestinal Carcinoma","Inclusion Criteria:\n\nAge at initial diagnosis: 18-75 years Histologically confirmed colorectal or small intestinal malignancy, with complete medical records, confirmed pathological diagnosis, and definitive staging data (TNM staging system) No history of other primary malignancies Absence of distant metastases (liver, lung, or other sites) confirmed by imaging examination (CT\u002FMRI) No prior surgical resection, chemotherapy, or PD-1\u002FPD-L1 immunotherapy before enrollment Availability of complete biospecimen information, including: Sample ID (medical record number), Demographic data (sex, age), Clinical diagnostic data, Tumor marker profiles (CEA, CA19-9, etc.)\n\nExclusion Criteria:\n\nLife expectancy \\\u003C6 months (as assessed by ECOG score ≥4 or Palliative Performance Scale ≤30%) Cognitive\u002Fpsychiatric conditions: a. Legally incapacitated individuals without legal guardians, b. Active psychotic disorders (e.g., schizophrenia, bipolar disorder) or dementia (MMSE score \\\u003C24) Investigator-determined exclusions","ALL","18 Years","75 Years",{"count":74,"type":75},200,"ESTIMATED","OBSERVATIONAL","The primary objective is to determine whether pretreatment-to-posttreatment changes in circulating multigene methylation levels correlate with objective response rates (ORR) assessed by contrast-enhanced CT\u002FMRI and levels of serum tumor markers. Secondary endpoints include: (a) time-dependent association between methylation fluctuation patterns and progression-free survival (PFS), (b) comparative diagnostic accuracy of methylation indices versus conventional biomarkers, and (c) feasibility of using methylation thresholds to guide adaptive therapy modification.",[79],"Intestinal Cancer","NOT_YET_RECRUITING","2025-05-18",{"date":83,"type":84},"2025-05-20","ACTUAL",{"date":86,"type":75},"2025-05-25",{"date":88,"type":75},"2030-03-01",{"name":5,"class":6},2]